Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Anti-IL12Rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders

Anti-IL12Rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders

US Patent 8574573 · Granted Nov 5, 2013

Estimated economic value: $9,329,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Anti-BAFFR antibody formulations and methods of use thereof2024
Clinical assessment of M-protein response in multiple myeloma2023
Treatment for multiple myeloma (MM)2023
Anti-IGF antibodies2022
Method of treating transplant rejection with silent Fc variants of anti-CD40 ant2021
Treatment for rheumatoid arthritis2021
Anti-BAFFR antibody formulations and methods of use thereof2021
Treatment for multiple myeloma (MM)2020
Nucleic acids encoding silent Fc variants of anti-CD40 antibodies2019
Anti-IGF antibodies2019
Nucleic acids encoding silent Fc variants of anti-CD40 antibodies2017
Silent Fc variants of anti-CD40 antibodies2017